MD2935B2 - Utilizare a xenonului pentru tratamentul neurointoxicatiilor - Google Patents

Utilizare a xenonului pentru tratamentul neurointoxicatiilor Download PDF

Info

Publication number
MD2935B2
MD2935B2 MDA20010349A MD20010349A MD2935B2 MD 2935 B2 MD2935 B2 MD 2935B2 MD A20010349 A MDA20010349 A MD A20010349A MD 20010349 A MD20010349 A MD 20010349A MD 2935 B2 MD2935 B2 MD 2935B2
Authority
MD
Moldova
Prior art keywords
xenon
neurointoxications
treatment
neurotransmitters
caused
Prior art date
Application number
MDA20010349A
Other languages
English (en)
Other versions
MD2935C2 (ro
MD20010349A (ro
Inventor
Christian Petzelt
Wolfgang J. Kox
Original Assignee
Aga Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7900688&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MD2935(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aga Ab filed Critical Aga Ab
Publication of MD20010349A publication Critical patent/MD20010349A/ro
Publication of MD2935B2 publication Critical patent/MD2935B2/ro
Publication of MD2935C2 publication Critical patent/MD2935C2/ro

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Inventia se refera la medicina, si anume la neurologie. In inventie este descrisa utilizarea xenonului sau a amestecurilor gazoase continand xenon pentru tratamentul neurointoxicatiilor. In particular, inventia se refera la utilizarea xenonului in acele cazuri, cand neurointoxicatia este cauzata de un exces de neuromediatori. Xenonul poate reduce eliberarea neuromediatorilor, in primul rand a dopaminei, care este cauzata de conditiile hipoxiei, cum ar fi apoplexia sau traumatismul craniocerebral.
MDA20010349A 1999-03-11 2000-03-08 Utilizare a xenonului pentru tratamentul neurointoxicaţiilor MD2935C2 (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19910986A DE19910986C2 (de) 1999-03-11 1999-03-11 Verwendung von Xenon bei der Behandlung von Neurointoxikationen
PCT/EP2000/002025 WO2000053192A1 (en) 1999-03-11 2000-03-08 Use of xenon for treating neurointoxications

Publications (3)

Publication Number Publication Date
MD20010349A MD20010349A (ro) 2002-02-28
MD2935B2 true MD2935B2 (ro) 2005-12-31
MD2935C2 MD2935C2 (ro) 2006-08-31

Family

ID=7900688

Family Applications (1)

Application Number Title Priority Date Filing Date
MDA20010349A MD2935C2 (ro) 1999-03-11 2000-03-08 Utilizare a xenonului pentru tratamentul neurointoxicaţiilor

Country Status (29)

Country Link
US (3) US6559190B1 (ro)
EP (1) EP1158992B2 (ro)
JP (1) JP4954373B2 (ro)
KR (1) KR100674407B1 (ro)
CN (1) CN1170544C (ro)
AR (1) AR022886A1 (ro)
AT (1) ATE248599T1 (ro)
AU (1) AU757361B2 (ro)
BG (1) BG105889A (ro)
BR (1) BR0010456A (ro)
CA (1) CA2367136C (ro)
CZ (1) CZ302864B6 (ro)
DE (2) DE19910986C2 (ro)
DK (1) DK1158992T3 (ro)
EE (1) EE200100480A (ro)
ES (1) ES2206202T5 (ro)
HK (1) HK1048073B (ro)
HU (1) HUP0201393A3 (ro)
IL (2) IL145177A0 (ro)
MD (1) MD2935C2 (ro)
NO (1) NO20014379L (ro)
PL (1) PL202941B1 (ro)
PT (1) PT1158992E (ro)
RS (1) RS49756B (ro)
RU (1) RU2246949C2 (ro)
SI (1) SI1158992T1 (ro)
SK (1) SK285111B6 (ro)
WO (1) WO2000053192A1 (ro)
ZA (1) ZA200107291B (ro)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9913677D0 (en) 1999-06-11 1999-08-11 Imperial College Formulation
GB9917822D0 (en) * 1999-07-29 1999-09-29 Imperial College Nmda antagonist
US6653354B2 (en) 1999-07-29 2003-11-25 Protexeon Limited NMDA antagonist comprising xenon
DE10045829A1 (de) * 2000-09-14 2002-04-04 Messer Griesheim Gmbh Volatile Anästhesiemittel mit Xenon
DE10054563A1 (de) * 2000-11-03 2002-05-16 Messer Griesheim Gmbh Verfahren und Vorrichtung zur Betonherstellung
US20020102211A1 (en) * 2000-12-07 2002-08-01 Renshaw Perry F. Use of magnetic resonance imaging in diagnosis of membrane fluidity-related disorders
GB0209998D0 (en) * 2002-05-01 2002-06-12 Protexeon Ltd Use
GB0210021D0 (en) * 2002-05-01 2002-06-12 Air Prod & Chem Ultrasonic gas analyser
CN1668315A (zh) 2002-06-12 2005-09-14 梅瑟·格里斯海姆有限公司 使用含氙气体进行脑保护
EP1521598A1 (de) * 2002-07-05 2005-04-13 Air Liquide Deutschland GmbH Xenon enthaltendes adjuvans
GB0218153D0 (en) * 2002-08-05 2002-09-11 Ic Innovations Ltd An analgesic agent for newborn or retal subjects
US7681572B2 (en) 2002-08-20 2010-03-23 Aga Ab Method and devices for administration of therapeutic gases
US7337776B2 (en) 2002-08-20 2008-03-04 Aga Ab Methods for easing pain and anxiety from atrial or ventricular defibrillation
FR2858233B1 (fr) * 2003-07-30 2008-04-11 Air Liquide Sante Int Medicament gazeux inhalable a base de xenon et de protoxyde d'azote
AU2004280118B2 (en) 2003-10-10 2009-01-15 Imperial Innovations Limited Use of xenon with hypothermia for treating neonatal asphyxia
WO2005039600A2 (en) * 2003-10-21 2005-05-06 Aga Ab Use of xenon for the prevention of programmed cell death
FR2863169B1 (fr) * 2003-12-08 2006-02-10 Air Liquide Sante Int Medicament gazeux inhalable a base d'argon pour le traitement des neuro-intoxications
EP1552840A1 (en) * 2004-01-07 2005-07-13 Aga Ab Use of a xenon/carbon monoxide mixture for the protection of cells
US7070005B2 (en) * 2004-02-10 2006-07-04 Planetair Turf Products, Llc Soil aerator assembly
WO2006017524A2 (en) * 2004-08-02 2006-02-16 Olney John W Preventing pathological increases in the rate of nerve cell suicide in immature nervous systems
WO2007075100A1 (en) * 2005-12-27 2007-07-05 Zakrytoe Aktsionernoe Obshchestvo 'atom-Med Center' Method for treating drug dependence
EP1980260A1 (en) * 2007-04-10 2008-10-15 Nicholas Peter Franks Use of hyperbaric conditions to provide neuroprotection
US8435569B2 (en) 2007-04-30 2013-05-07 Nnoxe Pharmaceutiques Inc. Pharmaceutical composition comprising at least one thrombolytic agent (A) and at least one gas (B) selected from the group consisting of nitrous oxide, argon, xenon, helium, neon
ITMI20071031A1 (it) * 2007-05-22 2008-11-23 Acetilene & Deriv Ati Siad Spa Uso di xenon per la protezione di organi da danno ischemico
WO2010035074A1 (en) * 2008-09-25 2010-04-01 Nnoxe Pharmaceutiques Inc Use of nitrous oxide, argon, xenon, helium, or neon, for the manufacture of a pharmaceutical composition for treating ischemic insults in patients who cannot be treated with thrombolytic agents
FR2952305B1 (fr) * 2009-11-10 2012-04-27 Air Liquide Medicament inhalable a base de xenon pour traiter ou pour prevenir les dyskinesies
WO2011081612A1 (ru) * 2009-12-31 2011-07-07 Bondarenko Vitaliy Leonidovich Применение криптона или ксенона в качестве противовирусного средства
FR2956323B1 (fr) 2010-02-15 2013-12-20 Air Liquide Medicament gazeux inhalable a base d'argon contre les deficiences ou defaillances d'organes peripheriques
FR2960779A1 (fr) 2010-06-08 2011-12-09 Air Liquide Medicament gazeux inhalable a base de krypton contre les deficiences ou defaillances d'organes peripheriques
FR2964036B1 (fr) 2010-08-24 2013-04-12 Air Liquide Medicament gazeux inhalable a base de krypton pour le traitement des neuro-intoxications
RU2583179C2 (ru) 2011-02-07 2016-05-10 ЭДВАНСТ ПРЕЗЕРВЕЙШНЗ ТЕКНОЛОДЖИЗ, ЭлЭлСи Способ консервации клеток и культур клеток
FR2975597B1 (fr) * 2011-05-24 2013-12-27 Air Liquide Utilisation de neon pour le traitement des neuro-intoxications, notamment des maladies enurodegeneratives et demyelinisantes
JP6046727B2 (ja) 2011-09-26 2016-12-21 アドバンスド プリザベイションズ テクノロジーズ リミテッド ライアビリティー カンパニー 生体組織の保存方法
RU2489154C1 (ru) * 2012-05-31 2013-08-10 Сергей Александрович Наумов Способ лечения вирусных гепатитов
CN103565745A (zh) 2012-08-10 2014-02-12 德克萨斯州大学系统董事会 用于治疗中风的神经保护性脂质体组合物和方法
FR2996457B1 (fr) 2012-10-09 2019-11-29 L'air Liquide,Societe Anonyme Pour L'etude Et L'exploitation Des Procedes Georges Claude Utilisation d'argon pour prevenir ou traiter les consequences neurologiques d'un choc septique
FR2996458B1 (fr) * 2012-10-09 2015-02-27 Air Liquide Utilisation de xenon pour prevenir ou traiter les consequences neurologiques d'un choc septique
FR2996459B1 (fr) * 2012-10-09 2015-02-06 Air Liquide Utilisation d'un melange argon/xenon pour prevenir ou traiter les consequences neurologiques d'un choc septique
PT2931291T (pt) 2012-12-11 2021-12-03 Mclean Hospital Corp Tratamento com xénon como complemento da psicoterapia para perturbações psiquiátricas
EP4082552B1 (en) 2013-03-15 2026-05-06 The Board of Regents of the University of Texas System Liquids rich in noble gas and methods of their preparation and use
FR3007983B1 (fr) * 2013-07-08 2015-06-26 Air Liquide Association de xenon et d'un antagoniste des recepteurs nmda pour lutter contre une maladie neurodegenerative
FR3022456B1 (fr) * 2014-06-20 2016-07-15 Air Liquide Xenon associe a un antagoniste des recepteurs nmda pour lutter contre une proliferation tumorale dans le systeme nerveux central
FR3027226B1 (fr) * 2014-10-17 2017-12-08 L'air Liquide Sa Pour L'etude Et L'exploitation Des Procedes Georges Claude Medicament pour traiter une maladie liee a un dysfonctionnement de la transmission synaptique dopaminergique
JP6622822B2 (ja) * 2015-06-23 2019-12-18 ノビリス セラピューティクス インコーポレイテッド 希ガス組成物を用いた治療的な免疫調節
US20180318338A1 (en) * 2015-11-09 2018-11-08 The Mclean Hospital Corporation Methods and compositions for the prevention of suicide, homicide and self-harming behaviors
US20170341980A1 (en) * 2016-05-31 2017-11-30 Noblis Therapeutics, Inc. Noble gas neuroprotection and neuroregeneration from treatment related neurotoxicity
US10485825B2 (en) * 2016-08-29 2019-11-26 Nobilis Therapeutics, Inc. Prevention of pregnancy complications by noble gas administration
RU2019116383A (ru) * 2016-10-31 2020-11-30 Нобилис Терапьютикс, Инк. Лечение тревожных расстройств и усиление противотревожных воздействий с помощью применения смесей, содержащих инертный газ
CN107569509B (zh) * 2017-02-22 2018-09-21 滨州医学院 氙或氙气体混合物在制备治疗癫痫的制剂中的用途
CN108986622A (zh) * 2018-08-16 2018-12-11 广州迈普再生医学科技股份有限公司 一种颅内血肿微创穿刺清除术培训装置及其制备方法
RU2712804C1 (ru) * 2018-08-29 2020-01-31 Жовнерчук Инна Юрьевна Способ коррекции функционального состояния человека в замкнутом пространстве
RU2789964C1 (ru) * 2022-04-01 2023-02-14 Александр Юрьевич Верховский Способ улучшения состояния кожи и подкожных тканей

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5099834A (en) * 1991-07-16 1992-03-31 Union Carbide Industrial Gases Technology Corporation Method for anesthesia
US5228434A (en) * 1991-07-16 1993-07-20 Praxair Technology, Inc. Mixture for anesthesia
US5357959A (en) * 1993-04-16 1994-10-25 Praxair Technology, Inc. Altered dipole moment magnetic resonance imaging method
AU688515B2 (en) * 1994-05-24 1998-03-12 F. Hoffmann-La Roche Ag Tricyclic dicarbonyl derivatives
RU2072241C1 (ru) * 1995-09-20 1997-01-27 Панина Елена Владимировна Способ формирования дыхательной газовой смеси и аппарат для его осуществления
US5846556A (en) * 1996-06-14 1998-12-08 Brooks; Bradley S. Inhalant for reducing stress and method of use
IT1286058B1 (it) * 1996-10-29 1998-07-07 Siad Societa Italiana Acetilen Procedimento e apparecchiatura per la purificazione e recupero dello xeno e altri gas nobili in sistemi anestetici
DE19709704C2 (de) * 1997-03-10 1999-11-04 Michael Georgieff Verwendung einer flüssigen Präparation von Xenon zur intravenösen Verabreichung bei Einleitung und/oder Aufrechterhaltung der Anaesthesie
DE19823606C2 (de) * 1998-05-27 2002-02-28 Draeger Medical Ag Verwendung von Perfluorcarbone in einem Atemgasgemisch sowie die Vorrichtung
GB9917822D0 (en) * 1999-07-29 1999-09-29 Imperial College Nmda antagonist

Also Published As

Publication number Publication date
PL350618A1 (en) 2003-01-27
PT1158992E (pt) 2004-01-30
US8143317B2 (en) 2012-03-27
HUP0201393A2 (en) 2002-09-28
SI1158992T1 (en) 2004-02-29
SK285111B6 (sk) 2006-06-01
EP1158992B1 (en) 2003-09-03
CN1359296A (zh) 2002-07-17
HUP0201393A3 (en) 2002-10-28
AU3287500A (en) 2000-09-28
SK12792001A3 (sk) 2002-07-02
EP1158992A1 (en) 2001-12-05
PL202941B1 (pl) 2009-08-31
CN1170544C (zh) 2004-10-13
AR022886A1 (es) 2002-09-04
NO20014379L (no) 2001-11-07
HK1048073A1 (en) 2003-03-21
YU65401A (sh) 2004-07-15
ATE248599T1 (de) 2003-09-15
AU757361B2 (en) 2003-02-20
JP4954373B2 (ja) 2012-06-13
KR20010108338A (ko) 2001-12-07
ZA200107291B (en) 2003-02-26
MD2935C2 (ro) 2006-08-31
WO2000053192A1 (en) 2000-09-14
KR100674407B1 (ko) 2007-01-26
IL145177A0 (en) 2002-06-30
DE60004974D1 (de) 2003-10-09
BG105889A (bg) 2002-04-30
EE200100480A (et) 2002-12-16
CZ302864B6 (cs) 2011-12-21
DE60004974T2 (de) 2004-07-22
DE60004974T3 (de) 2012-06-28
IL145177A (en) 2006-10-31
BR0010456A (pt) 2002-08-27
US6559190B1 (en) 2003-05-06
MD20010349A (ro) 2002-02-28
CA2367136A1 (en) 2000-09-14
DE19910986A1 (de) 2000-09-21
EP1158992B2 (en) 2012-02-01
HK1048073B (zh) 2005-06-03
JP2002538209A (ja) 2002-11-12
DE19910986C2 (de) 2001-06-07
US20030180375A1 (en) 2003-09-25
ES2206202T5 (es) 2012-05-22
CA2367136C (en) 2008-05-13
DK1158992T3 (da) 2003-12-29
ES2206202T3 (es) 2004-05-16
RS49756B (sr) 2008-04-04
NO20014379D0 (no) 2001-09-10
CZ20013234A3 (cs) 2002-06-12
RU2246949C2 (ru) 2005-02-27
US20070110821A1 (en) 2007-05-17

Similar Documents

Publication Publication Date Title
MD2935C2 (ro) Utilizare a xenonului pentru tratamentul neurointoxicaţiilor
JOP20210301A1 (ar) بيرولات ثلاثية الحلقة مكثفة كمُعدِّلات مضاد تريبسين ألفا-1
JOP20180009A1 (ar) مركبات مثبط فيروس hiv
WO2018234568A3 (en) HYDROXYNORKETAMINE FOR USE IN TREATING DEPRESSION
MA35342B1 (fr) Composés de-pipéridinyle utiles comme inhibiteurs de la tankyrase
MX2010002419A (es) (ciclopropilfenil) feniloxamidas, metodo para su produccion y uso como un medicamento.
MX2013003635A (es) Compuestos de n-heteroarilo.
DK2101792T3 (da) Anvendelse af carrageenan til behandling af rhinovirus-infektioner
JOP20140344B1 (ar) تركيبات وطرق لتقليل المضاعفات السلبية العظمي للقلب والاوعية الدموية
MA38253B1 (fr) Compositions comprenant de la vortioxétine et du donépézil
MX2021004819A (es) Composiciones y metodos para tratar lesiones cerebrales.
GEP201606595B (en) (r) -nifuratel, its use for the treatment of infections and synthesis of (r) and (s) –nifuratel
NZ756307A (en) Formulations of cannabinoids for the treatment of acne
NO20074780L (no) Heterocyklylamidsubstituerte imidazoler
TN2012000301A1 (fr) Utilisation du 2,3-dihydroxypropyl dodécanoate pour le traitement de la séborrhée
JOP20220319B1 (ar) أزيلاستين كعلاج مضاد للفيروسات
GEP20237472B (en) Oral care product
MA31369B1 (fr) Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1 -oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des traumatismes de la moelle epiniere
WO2005076761A3 (en) Composition for preenting a cold
MX2022003816A (es) Compuestos antibacterianos.
MX2022003814A (es) Compuestos antibacterianos de 4-quinolinona.
CL2004000984A1 (es) Forma de dosificacion oral de una sal de magnesio de (s)-pantopazol, para la profilaxis o tratamiento de una condicion asociada a inhibir la bomba protonica.
FR2945708B1 (fr) Formulations concentrees de cipc dans un dialcene glycol et leurs utilisations pour le traitement antigerminatif de bulbes ou tubercules
UA94781C2 (ru) Применение йота-каррагенана для профилактики или терапевтического лечения риновирусной инфекции
IS2849B (is) Notkun á írbesartani til framleiðslunnar á lyfjum sem eru notuð til að fyrirbyggja eða meðhöndla lungnaháþrýsting

Legal Events

Date Code Title Description
FG4A Patent for invention issued
PD4A Change of proprietorship (patent for invention)

Owner name: AIR PRODUCTS AND CHEMICALS, INC., US

Free format text: FORMER OWNER: AGA AB, SE; S-181 81 LIDINGO, SUEDIA

KA4A Patent for invention lapsed due to non-payment of fees (with right of restoration)
MM4A Patent for invention definitely lapsed due to non-payment of fees